(3aR)-5,5-bis(hydroxymethyl)-2,2-dimethyl-6,6a-dihydro-3aH-furo[2,3-d][1,3]dioxol-6-ol

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (3aR)-5,5-bis(hydroxymethyl)-2,2-dimethyl-6,6a-dihydro-3aH-furo[2,3-d][1,3]dioxol-6-ol
• 化学式: C₉H₁₆O₆
• 分子量: 220.22
• InChiKey: IQMIEGQNCDSYBA-AHXFUIDQSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.3
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  88.4
• 氢给体数：
  3
• 氢受体数：
  6

文献信息

• Carrier for use in delivering drug, conjugate, composition comprising same, and method for administrating same
  申请人：THE UNIVERSITY OF TOKYO

  公开号：US10912838B2

  公开（公告）日：2021-02-09

  The present invention provides a vesicle, a conjugate, a composition comprising the vesicle or the conjugate, for use in delivering a drug to the brain, and a method for administering the same. The composition of the present invention is a composition for administration to a subject according to a dosing regimen, comprising a carrier for drug delivery, wherein the dosing regimen comprises administering the composition to a subject who has been fasted or caused to have hypoglycemia and inducing an increase in blood glucose level in the subject, and the carrier is modified at the outer surface thereof with a GLUT1 ligand.

  本发明提供了一种囊泡，一种共轭物，一种包含囊泡或共轭物的组合物，用于向大脑递送药物，以及一种给药方法。本发明的组合物是一种用于按照给药方案给受试者给药的组合物，包含一种用于给药的载体，其中给药方案包括给禁食或导致低血糖的受试者给药该组合物，并诱导受试者血糖水平升高，载体在其外表面用GLUT1配体修饰。
• CARRIER FOR USE IN DELIVERING DRUG, CONJUGATE, COMPOSITION COMPRISING SAME, AND METHOD FOR ADMINISTRATING SAME
  申请人：The University of Tokyo

  公开号：US20180185501A1

  公开（公告）日：2018-07-05

  The present invention provides a vesicle, a conjugate, a composition comprising the vesicle or the conjugate, for use in delivering a drug to the brain, and a method for administering the same. The composition of the present invention is a composition for administration to a subject according to a dosing regimen, comprising a carrier for drug delivery, wherein the dosing regimen comprises administering the composition to a subject who has been fasted or caused to have hypoglycemia and inducing an increase in blood glucose level in the subject, and the carrier is modified at the outer surface thereof with a GLUT1 ligand.
• IMMOBILISED BIOLOGICAL ENTITIES
  申请人：CARMEDA AB

  公开号：US20210379253A1

  公开（公告）日：2021-12-09

  There is provided inter alia an anticoagulant surface which surface has covalently bound thereto a plurality of fragments of heparin, wherein said fragments consist of 5-18 saccharide units and at least some of said plurality of fragments comprise polysaccharide sequence A, which surface catalyses the inhibition of FIIa and FXa by AT.
• US9937263B2
  申请人：——

  公开号：US9937263B2

  公开（公告）日：2018-04-10
• [EN] IMMOBILISED BIOLOGICAL ENTITIES<br/>[FR] ENTITÉS BIOLOGIQUES IMMOBILISÉES
  申请人：CARMEDA AB

  公开号：WO2020070258A1

  公开（公告）日：2020-04-09

  There is provided inter alia an anticoagulant surface which surface has covalently bound thereto a plurality of fragments of heparin, wherein said fragments consist of 5-18 saccharide units and at least some of said plurality of fragments comprise polysaccharide sequence A, which surface catalyses the inhibition of FIIa and FXa by AT.